These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8531288)

  • 1. Carcinogenicity of lipid-lowering drugs.
    Newman TB; Hulley SB
    JAMA; 1996 Jan; 275(1):55-60. PubMed ID: 8531288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological and experimental applications to occupational cancer prevention.
    Vainio H; Hemminki K
    J UOEH; 1989 Mar; 11 Suppl():323-45. PubMed ID: 2664947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogenicity of lipid-lowering drugs.
    Tobert JA
    JAMA; 1996 May; 275(19):1480-2. PubMed ID: 8622219
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinogenicity of lipid-lowering drugs.
    JAMA; 1996 May; 275(19):1481-2. PubMed ID: 8622220
    [No Abstract]   [Full Text] [Related]  

  • 5. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration-required preclinical in vivo studies.
    Amerio A; Gálvez JF; Odone A; Dalley SA; Ghaemi SN
    Aust N Z J Psychiatry; 2015 Aug; 49(8):686-96. PubMed ID: 25916799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The carcinogenic effects of aspartame: The urgent need for regulatory re-evaluation.
    Soffritti M; Padovani M; Tibaldi E; Falcioni L; Manservisi F; Belpoggi F
    Am J Ind Med; 2014 Apr; 57(4):383-97. PubMed ID: 24436139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatment of hyperlipidemia in women.
    Walsh JM; Pignone M
    JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
    Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
    J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity.
    Snyder RD
    Environ Mol Mutagen; 2009 Jul; 50(6):435-50. PubMed ID: 19334052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do lipid-lowering drugs cause erectile dysfunction? A systematic review.
    Rizvi K; Hampson JP; Harvey JN
    Fam Pract; 2002 Feb; 19(1):95-8. PubMed ID: 11818357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics.
    Brambilla G; Martelli A
    Pharmacol Res; 2009 Jul; 60(1):1-17. PubMed ID: 19427580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients.
    Hayes AW; Dayan AD; Hall WC; Kodell RL; Williams GM; Waddell WD; Slesinski RS; Kruger CL
    Regul Toxicol Pharmacol; 2011 Jun; 60(1 Suppl):S1-34. PubMed ID: 21094668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
    Friedrich A; Olejniczak K
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering medication and risk of cancer.
    Olsen JH; Johansen C; Sørensen HT; McLaughlin JK; Mellemkjaer L; Steffensen FH; Fraumeni JF
    J Clin Epidemiol; 1999 Feb; 52(2):167-9. PubMed ID: 10201659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering drugs and risk for cancer.
    Pedersen TR
    Curr Atheroscler Rep; 2009 Sep; 11(5):350-7. PubMed ID: 19664378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies.
    Etminan M; Gill S; Samii A
    Pharmacotherapy; 2003 Jun; 23(6):726-30. PubMed ID: 12820814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.